Clinical Trials Browser

OTHER_GOV × Recurrence × Lymphoid × Clear all

Cytokine Release Syndrome, Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06961669 2025-05-29

ECAR01

Phase NA Recruiting

18 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05648019 2023-03-09

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Phase 2 Recruiting

40 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05137860 2022-01-18

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Phase 4 Unknown

56 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04699162 2021-01-14

HGMHRAEI/ALL

Completed

56 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Phase 2 Unknown

20 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Phase 2 Unknown

72 enrolled

Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03881761 2019-03-21

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Phase 1 Unknown

50 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT03881774 2019-03-21

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Phase 1 Unknown

20 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT03540303 2018-05-30

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Phase 1 Unknown

15 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT01300156 2011-02-21

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

Phase 2 Unknown

37 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Clinical Trials

NexCAR19

ECAR01

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

HGMHRAEI/ALL

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)